Proinsulin-Loaded Nanoparticles Suppress Insulitis and Induce Temporary Diabetes Remission

Area of Science:

• Immunology
• Endocrinology
• Nanomedicine

Background:

• Autoimmune type 1 diabetes (T1D) arises from a loss of immune tolerance to pancreatic beta cells.
• Restoring immune tolerance is a key goal for T1D translational research.

Purpose of the Study:

• To investigate the therapeutic potential of novel ultrasmall nanoparticles (NPs) for treating autoimmune diabetes.
• To evaluate the efficacy of NPs loaded with proinsulin (PI) and an aryl hydrocarbon receptor (AhR) agonist in a non-obese diabetic (NOD) mouse model.

Main Methods:

• Treatment of recent-onset diabetic NOD mice with PI- and AhR-agonist-loaded NPs for 4 weeks.
• Analysis of immune cell populations (CD8+ T cells, dendritic cells, B lymphocytes, regulatory T cells) in islets, spleen, and lymph nodes.
• Assessment of disease remission and immune tolerance markers (IL-10, Foxp3, IFN-γ).

Main Results:

• NP treatment induced temporary and sometimes durable diabetes remission in NOD mice.
• Short-term treatment led to rapid depletion of islet infiltrates, including CD8+ T cells and dendritic cells.
• Durable remission was associated with increased IL-10-producing B cells, regulatory T cells, and memory T cells.

Conclusions:

• Ultrasmall NPs loaded with PI and an AhR agonist show potential for treating recent-onset autoimmune diabetes.
• The observed immune modulation suggests a mechanism for restoring immune tolerance.
• This therapy may not be sufficient as a standalone treatment for long-term remission.